- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Eye Fixation.
Displaying page 1 of 2.
EudraCT Number: 2018-002877-23 | Sponsor Protocol Number: 1.0 | Start Date*: 2019-01-21 | |||||||||||
Sponsor Name:Abteilung für Neurologie der Medizinischen Universität Innsbruck | |||||||||||||
Full Title: Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. | |||||||||||||
Medical condition: Social functioning in Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005452-26 | Sponsor Protocol Number: SMR-2728 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:OptiNose AS | |||||||||||||
Full Title: A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate vari... | |||||||||||||
Medical condition: Autism spectrum disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008259-41 | Sponsor Protocol Number: OZR-2008-20 | Start Date*: 2009-03-30 |
Sponsor Name:Rotterdam Eye Hospital | ||
Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ... | ||
Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002931-32 | Sponsor Protocol Number: APL2-GA-305 | Start Date*: 2021-09-17 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration | |||||||||||||
Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) DE (Ongoing) CZ (Ongoing) PL (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004108-23 | Sponsor Protocol Number: 17097AB-AS | Start Date*: 2018-10-09 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Low-dose atropine eye drops to reduce progression of myopia in children: a multi-centre placebo controlled randomised trial in the United Kingdom (CHAMP UK) | ||
Medical condition: Myopia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005601-22 | Sponsor Protocol Number: poc1doxy | Start Date*: 2008-03-27 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ... | |||||||||||||
Medical condition: Diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001436-22 | Sponsor Protocol Number: APL2-303 | Start Date*: 2018-12-07 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A... | |||||||||||||
Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003260-12 | Sponsor Protocol Number: NTMT-03-B | Start Date*: 2018-10-02 |
Sponsor Name:Neurotech Pharmaceuticals Inc. | ||
Full Title: A Phase 3 Multicenter Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia type 2 | ||
Medical condition: Macular Telangiectasia type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001496-20 | Sponsor Protocol Number: SMR3438 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:Katairo GmbH | |||||||||||||
Full Title: A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease | |||||||||||||
Medical condition: Stargardt Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000265-33 | Sponsor Protocol Number: 3000LM | Start Date*: 2021-02-25 |
Sponsor Name:The Rotterdam Eye Hospital | ||
Full Title: Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations | ||
Medical condition: RPE65-associated inherited retinal degeneration | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014444-11 | Sponsor Protocol Number: RET04.09 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS | |||||||||||||
Full Title: Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib | |||||||||||||
Medical condition: Diabetic Macular Edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001435-52 | Sponsor Protocol Number: APL2-304 | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A... | |||||||||||||
Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003234-82 | Sponsor Protocol Number: NTMT-03-A | Start Date*: 2018-06-13 |
Sponsor Name:Neurotech Pharmaceuticals | ||
Full Title: A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2 | ||
Medical condition: Macular Telangiectasia type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004547-77 | Sponsor Protocol Number: RN03-CP-0001 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:ReNeuron Ltd | |||||||||||||
Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) | |||||||||||||
Medical condition: Retinitis Pigmentosa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002202-70 | Sponsor Protocol Number: | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein (UK-SH) | |||||||||||||
Full Title: A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (... | |||||||||||||
Medical condition: Retinal function in patients with wet age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000578-41 | Sponsor Protocol Number: GX28198 | Start Date*: 2012-12-05 | |||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB (FCFD4514S) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO HAVE COMPLETED GENENTECH-SPONSORED LA... | |||||||||||||
Medical condition: Geographic Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014269-25 | Sponsor Protocol Number: A0081096 | Start Date*: 2009-12-18 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO | |||||||||||||
Medical condition: EPILEPSY WITH PARTIAL SEIZURE | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013702-14 | Sponsor Protocol Number: BETNV009 | Start Date*: 2010-08-13 | ||||||||||||||||
Sponsor Name:Hospital of the University of Munich | ||||||||||||||||||
Full Title: Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial | ||||||||||||||||||
Medical condition: vestibular failure (vestibular neuritis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002109-20 | Sponsor Protocol Number: AAV2-hRPE65v2-301 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Spark Therapeutics, Inc. | |||||||||||||
Full Title: A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-h... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000490-37 | Sponsor Protocol Number: PR001 | Start Date*: 2008-02-26 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.